Phase II study of 2-methoxyestradiol (2ME2) NanoCrystal Dispersion (NCD) in patients with taxane-refractory, metastatic hormone-refractory prostate cancer (HRPC)
Year: 2008
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: M. R. Harrison, N. Hahn, R. Pili, W. K. Oh, K. Kim, G. Wilding, C. J. Sweeney, C. Sidor, J. Arnott, G. Liu
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2590237911